EXPERIENCE OF USE OF DRUG DIBICOR IN THE COMPLEX THERAPY OF NON-ALCOHOLIC FATTY LIVER DISEASE


Cite item

Full Text

Abstract

Effectiveness of use of taurine (Dibicor) in the treatment of non-alcoholic fatty liver disease (NAFLD) in the stage of steatohepatitis (NASH) was estimated. In the MCH № 7, Novosibirsk, 36 patients of both sexes with NASH with minimal biochemical activity received comprehensive treatment, 20 of them received the drug Dibicor. All patients underwent anthropometric and laboratory physical examination before the study and after 1 month of treatment. Statistical analysis of the results was performed using SPSS 13.0 software package with the definition of levels of statistical significance. Value of P<0.05 was considered statistically significant. Improvement of general condition was observed in patients of both groups. Side effects against the background of the treatment with drug Dibicor were not revealed. In the group treated with Dibicor, improved lipid profile, decreased levels of free bilirubin, fibrinogen, alkaline phosphatase, γ- glutamyltranspeptidase, glycemia, decreased body mass index and diastolic blood pressure were observed. It is concluded that Dibicor (taurine) is a physiological and safety drug with hepatoprotective and hypolipidemic effects in patients with NASH associated with obesity, and may be included in the treatment regimen of NASH.

References

  1. Аметов А.С., Кочергина И.И. Применение Дибикора при сахарном диабете и сердечно-сосудистой патологии // Эффективная фармакотерапия в эндокринологии. 2007. № 2. C. 40-49.
  2. Жуков Б.И. Оптимизация профилактики, диагностики и лечения первой степени артериальной гипертензии у детей подросткового возраста. Автореф. дисс. канд. мед. наук. Волгоград, 2007.
  3. Захаров И.В. Клиническая эффективность дибикора при лечении артериальной гипертензии у беременных. Автореф. дисс. канд. мед. наук. Волгоград, 2007.
  4. Звенигородская Л.А., Овсянникова О.Н., Носкова К.К. и др. Таурин в лечении неалкогольной жировой болезни печени // Экспериментальная и клиническая гастроэнтерология. 2010. № 7. С. 43-50.
  5. Мкртумян А.М., Подачина С.В., Петраченко В.В. Дибикор - эффективное и безопасное средство для лечения сахарного диабета // Эффективная фармакотерапия в эндокринологии. 2008. № 2. С. 34-39.
  6. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. Опыт применения Дибикора при сахарном диабете 2 типа // Сахарный диабет. 2007. № 1. C. 30-32.
  7. Cave M, Chen T, Mc Clain CJ, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009;50(6):1818-26.
  8. Chen SW, Chen YX, Shi J, et al. The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Dig Dis Sci 2006;51(12):2225-34.
  9. Chen W, Matuda K, Nishimura N, et al. The effect of taurine on cholesterol degradation in mice fed a high-cholesterol diet. Life Sci 2004;74(15):1889-98.
  10. Hu YH, Lin CL, Huang YW, et al. Dietary amino acid taurine ameliorates liver injury in chronic hepatitis patients. Amino Acids 2008;35(2):469-73. Epub 2007 Aug 10.
  11. Matsuoka T. Nagasaki Med J 1960;35(2):352. Miyata K, Ikawa O, Izumi H, et al. Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer. Gan To Kagaku Ryoho 2006;33(5):671-73.
  12. Oh M, Winn J, Poordad F. Aliment Pharmacol Ther 2008;28(5):503-22. Spencer AU, Yu S, Tracy TF, et al. Parenteral nutrition-associated cholestasis in neonates: multivariate analysis of the potential protective effect of taurine. JPEN J Parenter Enteral Nutr 2005;29(5):337-44.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies